Clonal competition and disrupted molecular processes in chronic lymphocytic leukemia.

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	ZÁVACKÁ Kristýna TAUŠ Petr PÁL Karol PORC Jakub Paweł PAVLOVÁ Šárka MALČÍKOVÁ Jitka STRÁNSKÁ Kamila ŽENATOVÁ Marcela TICHÝ Boris BLAVET Nicolas PANOVSKÁ Anna DOUBEK Michael POSPÍŠILOVÁ Šárka PLEVOVÁ Karla
Year of publication	2023
Type	Conference abstract
MU Faculty or unit	Central European Institute of Technology
Citation
Attached files	FEBS-Biochemistry_Congress_final_programme_abstract_book.pdf
Description	Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries. Due to dynamic clonal changes in a leukemic cell population over time, CLL is characterized by a highly variable clinical course. The expansion of subclones with different gene mutations, many of which are non-recurrent, makes CLL challenging to treat. We aimed to describe the clonal evolution in CLL, focusing on specific treatments and different stages of the disease. As defects in the TP53 gene are strong predictive and prognostic markers in CLL and drive chemoimmunotherapy resistance, we particularly studied factors influencing the clonal development of TP53-mutated subclones.
Related projects:	Advanced sequencing methods for deciphering structural variants in cancer genome National institute for cancer research Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit X